• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SLC18A2 Gene Record

  • Summary
  • Interactions
  • Claims
  • SLC18A2 6571 Druggable Genome

    Alternate Names:

    6571
    SOLUTE CARRIER FAMILY 18 MEMBER A2
    SLC18A2
    SVAT
    SVMT
    VAT2
    VMAT2
    193001
    10935
    ENSG00000165646
    OTTHUMG00000019121
    Q05940
    SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940]
    VMAT2_HUMAN
    SOLUTE CARRIER FAMILY 18 MEMBER 2
    SYNAPTIC VESICLE AMINE TRANSPORTER
    MONOAMINE TRANSPORTER
    Vesicular amine transporter 2
    Synaptic vesicular amine transporter
    PA325
    T48873
    PKDYS2

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Target Main Class Transporters
    Target Subclass SLC
    Transmembrane Helix Count 12
    Target Subclass SLC18
    Target Subclass MFS
    Target Class Transporters
    Target Subclass TC:2.A.1.2.29
    Gene Biotype PROTEIN_CODING
    (5 More Sources)

    Gene Categories: Category Details

    TRANSPORTER
    DRUGGABLE GENOME

    Publications:

    Biezonski et al., 2010, Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity., J. Neurochem.
    Hansen et al., 2002, Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity., J. Pharmacol. Exp. Ther.
    Horton et al., 2011, meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release., J. Pharmacol. Exp. Ther.
    Yasumoto et al., 2009, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2., Neurosci. Lett.
    Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
    Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
    Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
    Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol
    Mandela et al., Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles., Neurochem. Int.
    Naudon et al., 1995, Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex., Synapse
    Erickson et al., 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
    Sievert et al., 2007, Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels., Anal. Biochem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    SCHLAGEL et al., 1957, Rauwolfia hypotension. II. Action of the alseroxylon alkaloids and epinephrine on the carotid pressoreceptors., J Am Pharm Assoc Am Pharm Assoc
    FORD et al., 1958, Rauwolfia toxicity in the treatment of hypertension; comparative toxicity of reserpine and alseroxylon., Postgrad Med
    Loeffler et al., 1979, Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay., J Pharm Sci
    Fulton et al., 1976, Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines., Fed. Proc.
    Wimalasena, 2011, Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry., Med Res Rev
    Kim et al., 2009, Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells., J. Neurosci.
    Goland et al., 2009, 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls., J. Nucl. Med.
    Zheng et al., 2006, Vesicular monoamine transporter 2: role as a novel target for drug development., AAPS J
    Gros et al., 2010, Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter., J. Biol. Chem.
    Eiden et al., 2011, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse., Ann. N. Y. Acad. Sci.
    Teng et al., 1998, Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine., J. Neurochem.
    Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)
  • TETRABENAZINE   SLC18A2

    Interaction Score: 10.85

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name tetrabenazine,Nitoman
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    20135628 19571144 19223416 17233532 11752352 20007701


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • LOBELINE   SLC18A2

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name Lobeline

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • VALBENAZINE TOSYLATE   SLC18A2

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name NBI-98854
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • DESERPIDINE   SLC18A2

    Interaction Score: 5.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    574544 20176067 8525459 1438304 17559790 11134


    Sources:
    ChemblInteractions

  • ALSEROXYLON   SLC18A2

    Interaction Score: 4.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    13505370 13438725 17016423 17139284 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • ALKAVERVIR   SLC18A2

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DEXTROAMPHETAMINE   SLC18A2

    Interaction Score: 2.17

    Interaction Types & Directionality:
    inducer (activating)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR
    Novel drug target Established target
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    15955613 7751968


    Sources:
    TdgClinicalTrial ChemblInteractions

  • MIDOMAFETAMINE   SLC18A2

    Interaction Score: 1.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20002520 11861820


    Sources:
    TTD

  • RESERPINE   SLC18A2

    Interaction Score: 1.76

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    20176067 8525459 1438304 17559790 11752352 17016423 17139284 13438725 13505370


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • BENZPHETAMINE HYDROCHLORIDE   SLC18A2

    Interaction Score: 1.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • VALBENAZINE   SLC18A2

    Interaction Score: 1.63

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DEUTETRABENAZINE   SLC18A2

    Interaction Score: 1.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LISDEXAMFETAMINE DIMESYLATE   SLC18A2

    Interaction Score: 1.63

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes
    Trial Name Vyvanse

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • AMPHETAMINE   SLC18A2

    Interaction Score: 1.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name C105, levo-amphetamine sulfate
    Novel drug target Established target
    Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

    PMIDs:
    21272013 15955613 9648873 7751968 23539642


    Sources:
    TdgClinicalTrial

  • DEXTROAMPHETAMINE ADIPATE   SLC18A2

    Interaction Score: 1.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DEXTROAMPHETAMINE SULFATE   SLC18A2

    Interaction Score: 1.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • METHAMPHETAMINE   SLC18A2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    21177475 19429089 17209801 15955613 7751968


    Sources:
    TdgClinicalTrial

  • RESCINNAMINE   SLC18A2

    Interaction Score: 0.65

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BUPROPION   SLC18A2

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • Ensembl: ENSG00000165646

    • Version: 101_38

    Alternate Names:
    SLC18A2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: Q05940

    • Version: January-2014

    Alternate Names:
    SLC18A2 Gene Symbol

    Gene Info:
    Target Class Transporters
    Target Subclass TC:2.A.1.2.29

    Publications:

  • TEND: Q05940

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000165646 Ensembl Gene Id
    6571 Entrez Gene Id
    SLC18A2 Gene Symbol

    Gene Info:
    Target Main Class Transporters
    Target Subclass SLC
    Transmembrane Helix Count 12

    Publications:

  • RussLampel: ENSG00000165646

    • Version: 26-July-2011

    Alternate Names:
    SLC18A2 Display Id
    SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940] Description
    ENSG00000165646 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • PharmGKB: SLC18A2

    • Version: 18-August-2020

    Alternate Names:
    PA325 PharmGKB ID

    Gene Info:

    Publications:
    Mas S et al., 2016, Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes., Pharmacogenomics J
    Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol

  • HingoraniCasas: ENSG00000165646

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000165646 Gene Symbol
    SLC18A2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: SVMT

    • Version: chembl_23

    Alternate Names:
    VMAT2 GENE_SYMBOL
    SLC18A2 GENE_SYMBOL
    Synaptic vesicular amine transporter UNIPROT

    Gene Info:

    Publications:

  • TTD: Synaptic vesicle amine transporter

    • Version: 2020.06.01

    Alternate Names:
    SLC18A2 TTD Gene Abbreviation
    T48873 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: SLC18A2

    • Version: 01-February-2022

    Alternate Names:
    Synaptic vesicular amine transporter Gene Name
    Q05940 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSPORTER

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21